Drugs / MEN2312
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06638307 | Oct 2024 → Oct 2027 expected | female breast carcinoma | Stemline Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEN2312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06638307 ↗ |
| Action | Inhibit | “a lysine acetyltransferase 6 (KAT6) inhibitor” NCT06638307 ↗ |
| Route | Oral | “MEN2312 administered as oral tablets.” NCT06638307 ↗ |